Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Certus Molecular Diagnostics AG manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 2 matters are assigned to 1 distinct examiner and 1 distinct art unit, centralizing the company's current prosecution efforts. This concentration suggests that the company's active applications are closely related in technical scope. The presence of 2 pending office actions under a single point of review allows for a unified prosecution strategy across the company's docket.
The busiest examiner for the portfolio is HOPPE, EMMA RUTH, who is responsible for 2 busiest examiner pending office actions. Because this examiner handles all the pending workload, the company's progress is entirely dependent on the specific review of this individual official. For a practitioner, this means that the examiner's past behavior and preferred legal arguments are the most important factors to consider. The outcome of the 2 pending office actions will be determined by how well the company addresses the specific concerns of this official. Maintaining a consistent and persuasive dialogue with this examiner is essential for the portfolio's success.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOPPE, EMMA RUTH | 2 | 40.0% | +58.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18009142 | ISOTHERMAL REAL-TIME PCR METHOD FOR DETERMINING PRESENCE OF A PRE-DETERMINED NUCLEIC ACID SEQUENCE IN HUMAN SAMPLES | HOPPE, EMMA RUTH | — |
| 18008809 | ISOTHERMAL REAL-TIME PCR METHOD FOR DETERMINING PRESENCE OF A PRE-DETERMINED NUCLEIC ACID SEQUENCE OF A BACTERIUM OF THE MOLLICUTES CLASS IN A SAMPLE | HOPPE, EMMA RUTH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18009142 | ISOTHERMAL REAL-TIME PCR METHOD FOR DETERMINING PRESENCE OF A PRE-DETERMINED NUCLEIC ACID SEQUENCE IN HUMAN SAMPLES | HOPPE, EMMA RUTH | — |
| 18008809 | ISOTHERMAL REAL-TIME PCR METHOD FOR DETERMINING PRESENCE OF A PRE-DETERMINED NUCLEIC ACID SEQUENCE OF A BACTERIUM OF THE MOLLICUTES CLASS IN A SAMPLE | HOPPE, EMMA RUTH | — |
| Art Unit | Apps |
|---|---|
| 1683 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18009142 | ISOTHERMAL REAL-TIME PCR METHOD FOR DETERMINING PRESENCE OF A PRE-DETERMINED NUCLEIC ACID SEQUENCE IN HUMAN SAMPLES | HOPPE, EMMA RUTH | 1683 | §102§103§112Other | Final Rejection | — | Pending | Dec 08, 2022 |
| 18008809 | ISOTHERMAL REAL-TIME PCR METHOD FOR DETERMINING PRESENCE OF A PRE-DETERMINED NUCLEIC ACID SEQUENCE OF A BACTERIUM OF THE MOLLICUTES CLASS IN A SAMPLE | HOPPE, EMMA RUTH | 1683 | §103§112Other | Final Rejection | — | Pending | Dec 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCertus Molecular Diagnostics AG has 2 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Emma Ruth Hoppe has the most, with 2 of Certus Molecular Diagnostics AG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
